I-Mab
IMAB4.6300.00% ( 0.000 )
I-Mab (IMAB)
I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givas...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- 4.630
- Volume
- 0
- Turnover
- 0
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- 6.790
- Volume Ratio
- 0.00
- Turnover Ratio
- --
News
- PharmaTimes · Mar 23 at 07:56 AM
IsomAb appoints Philip Brainin as CEO
- Market Beat · Nov 4, 2025 at 05:46 PM
Short Interest in I-Mab Sponsored ADR (NASDAQ:IMAB) Increases By 38.8%
- Market Beat · Nov 1, 2025 at 12:13 PM
I-Mab's (IMAB) Sell (D-) Rating Reaffirmed at Weiss Ratings
- Tip Ranks · Oct 29, 2025 at 03:32 PM
NovaBridge Biosciences Unveils New Identity and Strategic Direction
- Tip Ranks · Oct 28, 2025 at 03:44 PM
I-MAB Completes Acquisition of Bridge Health Biotech
- Market Beat · Oct 28, 2025 at 04:26 AM
I-Mab Sponsored ADR (NASDAQ:IMAB) Receives Consensus Rating of "Moderate Buy" from Brokerages
